Gallen expert consensus also classifies HER2-positive breast tumors, negative for both ERα and PR but overexpressing HER2, as well as triple-negative breast cancers (TNBC), which express neither ERα nor PR and do not overexpress HER2 [2,3]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.